MentionFox
Home › funding signals › Theravie Pharma, Inc.
Form D · on the record

Theravie Pharma — $750K Form D filing, October 2026

Theravie Pharma, Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-19.

Theravie Pharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 19, 2026. The filing reports $750K sold. Its industry group is Biotechnology. It names Samia Almoughrabie (Executive Officer, Director), Richard Gallo (Executive Officer, Director) (SEC Form D, October 19, 2026).

5 more Biotechnology raises in California, October 2026 ↓

Sell to companies like Theravie Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

Run the free check on Theravie Pharma, Inc. →

Theravie Pharma, Inc.

New Form D on file · 2026-10-19 · the record

$750K
raise on the record
D
filing
1
investors in
CALIFORNIA
based
Open the record →

What the record says

FilingForm D
Filed2026-10-19
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
Year formed2025
BasedSAN DIEGO, CALIFORNIA
CIK2160768
Accession0002160768-26-000001

Pitching, partnering or investing alongside them? See who really runs and owns Theravie Pharma, Inc.

Watch Theravie Pharma, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Theravie Pharma, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in California, filed in October 2026, largest first.

What do you want to do with Theravie Pharma, Inc.?

Get the full cited report on Theravie Pharma, Inc.

What the filing shows about Theravie Pharma, Inc.

  • 1 investor had already put money in when it filed.
  • The filing names 2 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Theravie Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

What the filing says

  • Offered: $2,250,000. Sold: $750,000. Left to sell: $1,500,000. (filing)
  • Investors: 1 had already invested. (filing)
  • Date of first sale: September 29, 2026. (filing)
  • Types of securities: Equity; Other: Simple Agreement for Future Equity (SAFE), a contractual right to receive equity securities upon the occurrence of specified future financing events.. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Theravie Pharma, Inc. See pricing

Biotechnology · by week
This raise, $750K, filed week of Oct 19

Trailing twelve months. 768 filings in Biotechnology, totalled by week. The dot is this raise, $750K, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Theravie Pharma, Inc.?

What the filing shows about Theravie Pharma, Inc.

  • 1 investor had already put money in when it filed.
  • The filing names 2 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Theravie Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Theravie Pharma, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Theravie Pharma, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

RSS

Tools for this story

Each opens in a new tab, filled in for Theravie Pharma, Inc.. With no account yet, you sign up free and land on the result.

Share this page

Just raised? Share it.

Theravie Pharma, Inc.: Raised $750K, Form D filed 2026-10-19

Cite this page

Permanent URL: https://mentionfox.com/funding/theravie-pharma-inc-form-d-000001
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
Theravie Pharma raised $750K — SEC Form D filing, October 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/theravie-pharma-inc-form-d-000001